IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Review On Drug Discovery And Development

[1]Tanuja Bhausaheb Kolhe, [1]Gajanan Keshav Gajmal, [1]Ayaz Ahmad Aadam Shah, [1]Dhananjay Machindra Patil, [1]Deepak Devidas Sonawane.

[1] Shrishakti Shaikshanik Sanstha's Divine College Of Pharmacy, Nampur Road Satana, Baglan, Nashik, Maharashtra, India,423301.

Abstract : Finding a therapeutically effective molecule for the treatment and cure of disease is the goal of drug discovery. The selection of candidates, synthesis, characterisation, validation, optimization, screening, and tests for therapeutic efficacy are all parts of this process. A molecule will start the medication development process prior to clinical trials once it has demonstrated its importance in these studies. A new drug must go through a number of stages of development in order to be produced that is both safe and efficient and meets all regulatory standards. One overarching theme of our article is that because the process is so drawn out, expensive, and complex, numerous biological targets must be taken into account before any new medication is finally approved for clinical use. Additionally, new research tools may be required to examine each new target. It takes time and effort to develop a drug that can be sold. From the time of discovery until the treatment is licenced, it takes roughly 12 to 15 years and costs about US $1 billion. A million molecules are typically tested, but only one is examined in advanced clinical trials and ultimately made available to patients. An overview of the procedures for discovering and developing novel drugs is given in this article.

IndexTerms **- Lead optimization, clinical trials, target validation, identification, Clinical Phases, Clinical Phase Trials, Preclinical Trials, Federal Drug Administration.**

1. Introduction

The creation of new medications is a difficult, expensive, and dangerous process. Its success is heavily reliant on intense interaction and collaboration between numerous departments within the drug development organisation, external investigators, and service providers, as well as on ongoing communication with regulatory agencies, payers, academic experts, clinicians, and patient organisations. The initial and ongoing success of a drug on the market depends heavily on drug development, which is one of the phases of the drug life cycle[1] Starting with the straightforward technique of discovering an active molecule, the discovery of new drugs includes a synthesis of several disciplines and areas of interest. The process of developing a medicine does not begin with the identification of a novel chemical that alters the function of a cell or tissue. Before a substance to be regarded as a therapeutic entity, it must first be demonstrated to be efficient and selective, be completely devoid of toxicity, have good bioavailability, and be commercially viable.[2] The difficult process of creating a new drug from an initial concept to the release of a final product might take years. 12–15 years and more than $1 billion in cost. Academic research is one possible source for a target's notion. and medical research, as well as from industry. The process of accumulating a body of supporting evidence may take many years. In advance of choosing a target for an expensive drug discovery effort. After deciding on a target, the pharmaceutical Several early techniques to identify potential candidates would have been streamlined by industry and, more recently, some academic centres. molecules with the necessary qualities to produce medications that are acceptable.[3] Preclinical research using cell-based and animal models, human clinical trials, and finally securing regulatory approval to market the treatment are all steps in the development and discovery of new drugs. The identification of screening hits, medicinal chemistry, and optimization of those hits to improve their affinity, selectivity (to decrease the possibility of side effects), efficacy/potency, metabolic stability (to lengthen the half-life), and oral bioavailability are all important steps in modern drug discovery. Once a molecule has been found that satisfies all of these criteria, the process of developing the medicine will start before clinical trials.[4]

The initial target selection and validation will be the first preclinical step of the drug discovery process to be examined in this review. This review's main emphasis is on broad strategies and ideas for creating analytical techniques for the separation, identification, and quantification of active pharmaceutical ingredients (APIs), which can be used in a variety of ways across the whole drug development process. In order to establish the safety and effectiveness of a medication molecule on the human body, the review also examines the issues and factors that must be taken into account during the validation of analytical methods, clinical and pre-clinical studies.

- The Discovery and Development
- Preclinical Research. Preclinical Research. Drugs undergo laboratory and animal testing to answer basic questions about safety.
- Clinical Research.
- FDA Review.
- FDA Post-Market. Safety Monitoring.

Fig 1: Drugs

2. Drug Development Process

2.1 Drug discovery and development

New medication research and discovery is a time-consuming and expensive procedure. R and D decisions in the research-based pharmaceutical sector have significant long-term effects, and changes in the market or in governmental policy may not have their full effect for many years. Therefore, it is crucial to keep examining the elements and trends in the costs of pharmaceutical innovation from both a policy and an industry perspective.[5] From the first identification of a prospective target through the finished drug, the development of drugs is an expensive, drawn-out, and gradual process.The final objective is to locate a molecule that has the desired impact on the human body and to confirm its efficacy, safety, and quality for patient treatment. The latter conditions ensure that the approved drug enhances the patient's quality of life by ensuring that the cure does not result in additional issues, including side effects, in addition to treating the patient's sickness. This implies that the process will be unusually expensive and drawn out. Currently, it costs about US$800 million to bring a single new medicine to market; this cost doubles every five years.[6]

Fig 2 : Drug appearance- Tablet and Capsule

Toxicity: The medications might not have an impact on every cell or tissue. Adverse drug reactions are another name for drug toxicity (ADR). Drugs turn become toxins when a patient consumes an excessive amount of them or when they interact with other medications to cause side effects like respiratory suppression, low oxygen levels, and ultimately death.[7]

The following three factors affect the cost of drug development

1. Amount of compounds synthesised: Only one medication is commercially available out of the 5000–10,000 compounds investigated.
2. The lead molecule's nature: If the lead molecule is made in an expensive manner, the production cost will be high.
3. The requirements of regulatory agencies before a drug is released onto the market have substantially increased. Standards needed for new drugs. Each medicine had a discovery phase cost of roughly $350 million. Another $150 million was spent on the Food and Drug Administration procedures I, II, and III. The amount now equals roughly $500 million for each medicine made available to customers.

The following desired characteristics of a therapeutic molecule should be understood.[8]

- Drugs must be both effective and safe.
- Drugs should possess a high bioavailability rate.
- Drug needs to have a lengthy half-life and be biologically stable.
- Drugs should have few, if any, negative effects and be harmless.
- Drug distribution to target tissues or disease states should be selective.

Stages of drug discovery and development include

- Target identification
- Target validation
- lead identification
- lead optimization
- Product characterization and Formulation and development
- Preclinical research
- Investigational New Drug

- New Drug Application
- Clinical trials
- Approval

Current Technologies of Interest for the Drug Development Process



Figure 3 : Stages of drug discovery and development process.[9]

2.1.1 TARGET SELECTION:

The choice to concentrate on discovering a substance with a specific biological action that is predicted to have therapeutic value is referred to as target selection in the context of drug development. This choice is impacted by a complex interplay of scientific, medical, and strategic factors.

2.1.1.1Target identification

Drugs fail in clinical trials for two main reasons: first, they are ineffective, and second, they are unsafe.As a result, target selection and validation is one of the crucial stages in the development of a novel medicine. A target is a general term that can be used to refer to a variety of biological things, such as proteins, genes, and RNA. A good target must be effective, safe, suit clinical and business goals, and most importantly, be "druggable." When a potential drug molecule, whether it be a small molecule or a larger biological, binds to a "drug-gable" target, it causes a biological reaction that can be observed both in vitro and in vivo. It is currently understood that some target classes, such as G-protein-coupled receptors (GPCRs), are more receptive to small molecule drug development, whereas anti-bodies are effective at blocking protein/protein interactions. We can have more confidence in the connection between the target and the disease thanks to effective target identification and validation, and we can investigate if target modulation will result in mechanism-based side effects.[10]

2.1.1.2 Target validation

In accordance with the suggested mode of action, the drug target must undergo experimental validation. Here, data (i.e., research in human cells/tissues of paramount relevance) directly relate to the likelihood of clinical success. Functional studies can use genetic knockdown, knockout, or, if SMOL drugs or tool antibodies are available, target-specific tools. Mechanistic research based on in vitro cells can be utilised to identify targets' regulatory properties and the pathways through which they function. Finally, based on the disease, it may be required to test the viability of a certain target in suitable animal models. Knockout or transgenic animals can be utilised for target validation if functional orthology between mice and humans is provided and appropriate disease models are available. The drug target must go through experimental validation in accordance with the proposed mode of action. The possibility of therapeutic success is directly correlated with the data (i.e., study on human cells/tissues of paramount value). When SMOL drugs or tool antibodies are available, functional studies can also use genetic knockdown, knockout, or target-specific tools. It is possible to use mechanistic research based on in vitro cells to pinpoint targets' regulatory characteristics and the pathways by which they work. Finally, depending on the disease, it could be necessary to examine the effectiveness of a particular target in appropriate animal models. If functional orthology between mice and humans is provided and suitable disease models are available, knockout or transgenic animals can be used for target validation.

Additionally, while rodents are used in the majority of mechanistic animal studies, some diseases are exclusive to higher primates. As a result, at this early stage of drug research, not all indication-specific problems can be solved.[11]

Target validation consists of two essential processes.

Reproducibility: The initial step after identifying a drug target, whether through the use of a particular technology or by a review of the literature, is to repeat the experiment to ensure that it can be effectively replicated. Affinity chromatography, expression cloning, protein microarray, reverse transfected cell microarray, biochemical suppression, siRNA, DNA microarray, system biology, and analysis of currently available medications are all components of the target validation technique. [12,13]

Introduce variation to the ligand (drug)-target- environment

- Target gene genetic manipulation (in vitro), gene knockdown (shRNA, siRNA, miRNA), and gene deletion the gene (using CRISPR), introducing genes (viral transfection of mutant genes)
- high-affinity antibodies that bind to the target and prevent further interactions

genomics of chemicals chemical defences against proteins encoded by the DNA.[14]

2.1.1.3 Cellular and genetic target:

involves determining the purpose of a prospective therapeutic medication target and its part in the development of the disease. This stage of the procedure entails identifying the target receptors or enzymes for tiny molecular medications, whereas for some biologic techniques, the focus is on the gene or transcription level. Drugs typically affect the body's cellular or genetic molecules, or targets, which are thought to be connected to disease.

Different methods are used by scientists to locate and study certain targets in order to understand how they work and how they affect disease. The next step is to identify compounds that interact in a variety of ways with the therapeutic targets and may be useful for treating a particular condition.

2.1.1.4 Genomics:

the investigation of genes and how they work. Genomics strives to comprehend the structure of the genome, including the mapping genes and sequencing the DNA. seeks to identify new therapeutic targets by making use of information obtained from the sequencing of the human and other genomes. The 3 billion nucleotides (A C G T bases) that make up the human genome are thought to encode 35,000–50,000 genes.

According to Drew, there are approximately 1,000 genes that are thought to be involved in disease, including those brought on by single-gene abnormalities and those caused by combinations of genes. He suggests that there could be between 5,000 and 10,000 possible therapeutic targets, assuming that each gene has 5 or 10 related proteins. SNP libraries are used to compare the genomes of healthy and diseased persons and to pinpoint the genomic differences between them.

2.1.1.5 Proteomics:

It involves applying methods for large-scale protein isolation and identification to investigate the proteome, or the entire collection of proteins generated by a species. It is becoming increasingly clear that proteins are where biological systems' complexity lies and that understanding these systems through genomes alone is insufficient. Additionally, illness processes emerge at the protein level, where most medications (91%) also exert their effects. In order to find new targets, it will consequently be crucial to analyse proteins (including protein-protein, protein-nucleic acid, and protein ligand interactions).

The high throughput, systematic separation and characterisation of proteins in biological systems is known as proteomics. Proteomic target identification is carried out by contrasting the levels of protein expression in healthy and sick tissues. The protein is separated using 2D PAGE before being fully identified and characterised by LC-MS/MS.

2.1.1.6 Bioinformatics:

The goal of bioinformatics, a subfield of molecular biology, is to advance biological research by massive computer analysis of biological data.

It plays a key role in various stages of the drug discovery process including

•Target identification

• Computer screening of chemical compounds and

• Pharmacogenomics [15]

2.1.2 LEAD DISCOVERY:

2.1.2.1 Identification of Lead

In the lab, 5–50 000 compounds are evaluated, but only 100– 200 of them are refined enough to be tested on systems in vitro and in vivo. Following the identification of the therapeutic target, researchers must locate one or more leads (chemical compounds or molecules, for example) that interact with the therapeutic target to provide the desired therapeutic effects, such as through antiviral or antibacterial activity. Researchers must test a wide range of chemicals on one or more targets in order to identify the ones whose pharmacological characteristics are most likely to provide the necessary therapeutic effects.

Biologists first check to see if the chemicals they have chosen have the desired therapeutic or antiviral effects on the target. Then, they use in vitro cellular and/or tissue systems to examine the compounds' relative toxicity or, in the case of a vaccination, their viral activity. Finally, they examine the animals' in vivo bioavailability. cellular and/or tissue systems created in vitro. Finally, they examine the animals' in vivo bioavailability.

A synthetically stable, workable, drug-like molecule that is active in both primary and secondary assays and exhibits adequate specificity, affinities, and selectivities for the target receptor is referred to as a chemical lead. In order to do this, the structure–activity connection must be defined, the viability of a synthetic process must be determined, and there must be some preliminary evidence of in vivo efficacy and target engagement. Among a chemical lead's characteristics are :

SAR defined

- Drug ability (preliminary toxicity, hERG)
- Synthetic feasibility
- Select mechanistic assays
- In vitro assessment of drug resistance and efflux potential
- Evidence of in vivo efficacy of chemical class
- PK/Toxicity of chemical class known based on preliminary toxicity or in silico studies.

A drug ability assessment is frequently carried out in order to reduce the number of compounds that fail in the medication development process. In order to turn a compound from a lead molecule into a medication, this evaluation is crucial. A substance must have the capacity to bind to a particular target in order to be regarded as druggable; nevertheless, the substance's pharmacokinetic profile with relation to absorption, distribution, metabolism, and excretion is also crucial. Other tests, including as the Ames test and cytotoxicity assay, will assess the compound's potential toxicity in screening.[16,17]

2.1.2.2 Lead candidate optimization

Duration: From 4 to 6 months

The physiochemical characteristics, pharmacokinetic behaviour, and therapeutic efficacy of the 100 to 200 selected chemicals are perfected in the lab. Twenty (20) will be chosen to undergo testing.The goal of this stage is to improve the molecules or compounds that show promise as possible medications, keeping only a small number of them for the following steps. These compounds are optimised by scientists using cutting-edge methodology. In silico (computer) modelling and X-ray crystallography, for instance, are used to examine how the chosen molecules attach to the therapeutic target, such as a protein or an enzyme. By screening, these data enable medical chemists to alter the structure of the chosen molecules or compounds, if necessary, and produce structural analogues.

The previous stage's "Leads" molecules are put through optimization treatment. This stage is thought to be crucial in the process of finding new drugs. Leads are adjusted at this point to produce "best" analogues with enhanced potency, effectiveness,

pharmacokinetic, and pharmacodynamic characteristics. Chemical alterations that are selected through structural activity analysis are used to effect the changes. Structure-based design could also be used to introduce the changes if the goal structure is understood. This stage is time-consuming and expensive because it entails simultaneously optimising numerous parameters. Lead optimization is considered to be a rate-limiting phase in the entire drug discovery process.[17,18]

2.1.3 MEDICINAL CHEMISTRY:

Pharmaceutical chemists create and/or choose suitable substances for biological testing that, if found to be active, could be used as lead substances. They next assess the efficacy and safety of comparable drugs' structure-activity relationships (SARs) in vitro and in vivo. In order to foresee issues and interpret advances to assist the project move forward, medicinal chemists working on drug discovery nowadays must be knowledgeable about a variety of other disciplines in addition to organic chemistry. The function of the medicinal chemist has altered dramatically during the past 25 years, as this article has emphasised. The data from in vivo testing was the main source of information for medicinal chemists during the early stages of drug discovery (from 1950 to roughly 1980). That earlier and relatively straightforward landscape has changed in the more recent ('now') period (roughly 1980 to the present), thanks to the development of new technologies like high-throughput in vitro screening, large compound libraries, combinatorial technology, defined molecular targets, and structure-based drug design. Although the medicinal chemist has access to a wide range of new options thanks to these new technologies, transferring in vitro activity into in vivo activity has been more difficult than expected due to the proliferation of additional safety standards. The knowledge base supporting drug research has grown significantly concurrently, making it more difficult for chemists to comprehend their areas of specialisation. Additionally, it has grown increasingly difficult to demonstrate appropriate clinical safety and efficacy in people, and regulatory bodies now want a growing volume of data. In truth, the number of launches of new medications in the form of novel molecular entities (names) has been generally declining for more than a decade, despite the application of numerous new technologies and the expanding resources and funding for drug development. Clearly, during the past 20 years, drug research has become more challenging and sophisticated. In this essay, we will address how these changes have affected medicinal chemists' roles and offer suggestions on how to make their contributions to the drug discovery process more effective.[19]

2.1.4 INVITRO STUDIES:

Research aimed at finding potential medication candidates must include in vitro experiments. In vitro approaches have been developed to explore several aspects of drug disposal in response to the demand for predictive information. These include metabolite profiling in various model species and humans, metabolic stability, elucidation of elimination pathways, potential for CYP enzyme inhibition, potential for CYP450 enzyme induction, and absorption. These studies aren't always carried out in accordance with legal requirements. However, many of these in vitro studies turn into crucial evidence for IND submission and post-IND filing from both the preclinical and clinical spheres.[20]

The phrase "this part prescribes good laboratory practises for conducting nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the Food and Drug Administration" is used to describe what is known as a "nonclinical laboratory study."

A "nonclinical laboratory study" is an in vivo or in vitro experiment in which test substances are evaluated for safety prospectively in test systems in a laboratory setting. Basic exploratory studies to ascertain a test article's utility or to ascertain its physical or chemical properties are not included in the definition of the term.[21]

2.1.5 INVIVO STUDIES:

In contrast to in vitro investigations, in vivo studies are carried out inside a living creature. This occurs in animal test subjects during preclinical studies. In vivo studies can be conducted on either people or animals, and they can be used in clinical trials. By demonstrating how a drug affects the body as a whole rather than just isolated cells, in vivo studies are able to solve a significant shortcoming of in vitro studies. This makes it possible for in vivo studies to more clearly see potential interactions, which can help them forecast a drug's safety, toxicity, and effectiveness. This aids scientists in predicting how potential medications will affect human disease.

In vivo investigations have their own significant drawbacks despite the fact that they address the problem with in vitro studies. Significant ethical issues surround in vivo research, particularly for preclinical investigations where only animal models are allowed. Animal testing has been the subject of a long-running ethical controversy. Preclinical in vivo research Scientists who desire to perform preclinical studies with animals must show that no other alternative methods can be utilised to carry out the experiment. At the moment, the rules and legislation governing animal testing are becoming more stringent. Additionally, they must exhibit balance, i.e., that the advantages of the study (knowledge gained) exceed the disadvantages (suffering caused to the animals). In vivo investigations are evolving technologically, just like in vitro studies have. Complex animal models will become easier to conduct, more affordable, and quicker thanks to emerging technologies like Crisper.Even with the enormous ethical challenges they face, in vivo investigations are expected to continue to be an integral aspect of preclinical research. Preclinical technologies are expected to significantly progress in the future, both in vitro and in vivo, which should make it easier to collect more precise data and use quicker and easier procedures. These developments are anticipated to increase the calibre of preclinical data and decrease the reliance on conventional animal models. [22-24]

2.1.6 Preclinical Testing

Pre-clinical research is used to assess a drug's efficacy and safety in animal species with an eye toward potential human outcomes. The relevant regulatory authorities must also approve the preclinical trials. The regulatory authorities must make sure that clinical studies are carried out in a safe and ethical manner and will only approve medications that have been proven to be both effective and safe. A fundamental set of technical requirements for acceptable preclinical drug development has been defined by ICH.[25]

Pre-clinical studies can be carried out in one of two ways: toxicology and pharmacology. Pharmacology is the study of the the drug's pharmacokinetic and pharmacodynamic characteristics. Investigating adverse pharmaceutical effects is crucial in the use of appropriate animal models and their oversight in toxicological studies. Making pharmacokinetic studies is crucial. In terms of absorption, distribution, metabolism, and excretion, it is understood the factors governing safety and effectiveness. These Studies provide data on absorption rates for various routes. selection of the dose form is aided by the mode of administration. dissemination, metabolism, and elimination rates; which controls the drug's half-life. Drug's half-life provides clarification of the drug's mandatory safety profile for regulatory bodies to give a medicine their approval. that drug the treatment process is revealed by the distribution drug's effectiveness as it relates to other medications affinity and bioavailability. The results of drug metabolism are likelihood of

progressing through biotransformation process phases synthesis of drug metabolites, etc. It also supports gaining knowledge of the processes and enzymes involved in biotransformation.[26]
In vitro and in vivo tests that assess the toxicological effects of the substance can be used in toxicological investigations. of the medicine. In-vitro tests can be carried out to examine the direct impacts on cell phenotypic and proliferation. In-vivo Studies for both qualitative and quantitative data can be conducted. effects of toxicology determination. As prevalent as drugs selecting the proper animal for the species is crucial. species to research toxicity. In-vivo tests to assess effects of drugs and poisons, including manner of action action, are frequently utilised to justify the intended application of the product in research projects.[27]

2.1.7 The Investigational New Drug Process (IND)

Before beginning clinical testing, drug developers must submit an Investigational New Drug application to the FDA.[28] In the IND application, developers must include:
• Preclinical and toxicity study data
• Drug manufacturing information
• Clinical research protocols for studies to be conducted
• Previous clinical research data (if any)
• Information about the investigator/ developer [29]

2.1.8 Clinical trials

Pharmaceutical, biological, and medical device manufacturers must guarantee product safety and show a medical benefit both in persons and the product is mass produced. Clinical trials precede preclinical development, and the key objectives are to evaluate the intervention's effectiveness and safety. Absorption, distribution, metabolism, and excretion studies, as well as toxicity tests, are all possible research topics. Before clinical tests, both in vitro and in vivo, are carried out. studies on the organs that are affected by toxicity long-term mutagenic consequences or mammalian reproductive impacts. Typically, there are two types of animals used in research on drug development. The animal that most correlates with studies on humans is chosen larger animal species are typically used in medical device research. The No Observed Adverse Effect Level (NOAEL), which is determined based on preclinical trials, is the level of exposure at which there is no biologically or statistically significant increase in the frequency or severity of any adverse effects in the exposed population when compared to its appropriate control. These are used to establish the initial active pharmaceutical ingredient (API) per mass patient dosage levels for Phase I clinical trials.
Clinical trials—defined as "scientifically controlled assessments of the safety and effectiveness of a therapeutic agent using consenting human subjects"—are initiated if preclinical research demonstrates that the therapy is both safe and effective. The US Food and Drug Administration (FDA) role starts after preclinical evaluation for safety and effectiveness. There are four possible outcomes: 1) the new treatment has a large beneficial effect and is superior to standard treatment; 2) the new treatment is equivalent to standard treatment; 3) the new treatment is neither clearly superior nor clearly inferior to standard treatment; or 4) a new treatment is inferior to standard treatment. These prospective studies must follow the guidelines of acceptable clinical practises and are created to address particular queries about biological or behavioural therapies.[30-34] Classification of the trial may take into account the investigators' methods (observational versus interventional clinical trials), the trial's objectives (prevention, screening, diagnostic, therapeutic, quality-of-life, or expanded access clinical trials), or whether the trial's design permits modifications based on information gathered during the trial (fixed versus adaptive clinical trials). Protection of human subjects, sampling, degree of masking, randomization, intention to treat analysis, selection of interventional and comparison groups, selection of end points, interpretation of results, trial duration, and decision between traditional versus equivalence testing are ten areas that are carefully examined in these clinical studies. The gold standard is randomised controlled trials (RCT), which are frequently used to assess the effectiveness of various medical interventions and may reveal information concerning unfavourable effects. [35-39] The study design (parallel-group, crossover, cluster, or factorial), the result of interest (efficacy versus effectiveness), and the evaluation of a hypothesis are all categories of RCTs (superiority, noninferiority, or equivalence) [40,41]. Phases 0, I, II, III, IV, and V of clinical trials are milestones in the research to ascertain if an intervention will be beneficial or hazardous to humans.[42,43]
Pharmacodynamics and pharmacokinetics are established in Phase 0. Sentry studies are carried out in Phase IV, comparative effectiveness research is carried out in Phase V, community-based research is carried out in Phase VI. Although this sounds simple and straightforward, definitions and purposes of the different phases become muddied, and studies to determine if a therapy should be used in the general population of patients may be complex and result in negative findings. Clinical studies may have unanticipated changes to the population being researched, the endpoints, or the analysis plan.[44] Understanding the basis of clinical trial phases will help researchers plan and implement clinical study protocols and, by doing so, improve the number of therapies coming to market for patients.

2.1.8.1 Phase 0 Clinical Trials

The National Institutes of Health (NIH) announced a number of initiatives in September 2003 to address the growing problem of getting new findings from fundamental science into the hands of patients. Strengthening the infrastructure for clinical research was one of the goals.[45] Following this, an FDA report titled "Challenge and Opportunity on the Critical Path to New Medical Products" was published in March 2004.[46] Between 1993 and 2003, US pharmaceutical R&D spending and the NIH budget both saw significant increases, yet the number of key drugs and biological product submissions to the FDA fell. From 1995 to 2000, $1.1 billion was needed for one successful medicine launch; from 2000 to 2002, $1.7 billion was needed. The critical path was difficult, ineffective, and expensive. It starts when prospective items are chosen for development. Clinical failure includes ineffectiveness and safety issues. The growing distance between knowledge and clinical usage, along with stagnation and decreased innovation, was cause for alarm. Phase I medication trials began in 2000, yet the likelihood of it reaching the market was no higher than it was in 1985.[47] Improvements in early clinical trial failure prediction reduce development costs and time to market.[48] This FDA analysis led to the idea of exploratory inquiry new drug (IND) trials, which can aid in identifying whether a known mechanism of action can also be observed in people, offer data on pharmacokinetics, choose potential products from a pool of candidates, and assess biodistribution. These studies are meant to aid in the decision-making process of whether or not to approve a treatment early in the research process utilising human models rather than relying on animal data. Early in clinical phase investigations, exploratory IND studies, often called Phase 0 studies, include little human exposure and don't have a therapeutic or diagnostic goal. About 10 trial participants receive subtherapeutic doses while being closely supervised by the clinical researcher. The average length of a patient's involvement is less than one week. Studies are done on pharmacodynamics and pharmacokinetics. These investigations

precede the customary dose escalation, safety, and tolerance tests; they do not exchange the Phase I clinical trials; and they do not demonstrate if a medication improves the pathology being treated. Before potential medicines enter Phase I research, these studies assist in removing them from consideration.[49-51] These studies were designed to shorten the critical path for drug development, investigate the human pharmacokinetic and pharmacodynamic profiles of INDs, aid in the quicker discovery of medications with high potential, and cut back on development expenses. The lack of therapeutic intent, patient motivation, potential delays or exclusions from other clinical trials with therapeutic intent, the relationship between microdosing pharmacokinetics and therapeutic dose, and the accessibility of sensitive analytical methods are all limitations of these trials.[52] High rates of attrition and just 8% of companies enter the market.

2.1.8.2 Phase I Clinical Trials

In a Phase I clinical study, the optimal drug administration method, drug frequency and dose, maximum tolerated dose (MTD), and adverse effects are assessed. Evaluations are made of the pharmacokinetics, pharmacodynamics, and tolerability. These Most importantly, investigations establish the treatment's safety. Trials typically have between 20 and 100 patients, and the clinical researcher oversees them. Patients are examined to see if they are responding to the medication and doses are raised if there are no serious side effects. The best and safest dose that can be given is determined using these escalation dose studies, which is a small fraction of the level that was harmful to animals during testing. Phase I trials' major objective is to avoid subject exposure to subtherapeutic dosages while preserving subject safety and quick accrual.[53] Most of the time, subjects are healthy volunteers, but occasionally, patients with a Some diseases might be necessary. These investigations are typically carried out by contract research groups, and compensation may be provided. Data is typically evaluated after each patient or small group of patients throughout testing, which is typically consecutive. This phase includes single ascending dose trials (Phase IA), multiple ascending dose trials (Phase IB), and dietary effect studies in order to establish dose-toxicity and dose-efficacy curves. Dose escalation techniques might be model- or rule-based. Rule-based designs permit escalation and de-escalation of the dose with diminishing fractions of the preceding dose depending on the presence or absence of toxicity and do not require any prior assumptions regarding the dose-toxicity curve. Cohorts of 3 patients are used to progress in the classic 3 + 3 design. Based on extrapolation from animal toxicity data, the starting dose was determined. Predetermined increasing dose levels typically follow a modified Fibonacci sequence, where the dosing increments get smaller as the dose increases.[54] Three further patients will be treated at the next higher dose if none of the patients suffer a dose-limiting toxicity. The same dose is administered to three additional patients if one of the patients develops dose-limiting effects. The dose is increased until at least two individuals from a cohort of three to six suffer from toxicities that are dose-limiting. The dose level just below the hazardous dose level is referred to as the recommended dose for the Phase II trial.

The "2 + 4," "3 + 3," and "3 + 1 + 1" ("best of five") rules are additional rule-based dose escalation techniques.[55] If a dose-limiting hazard is detected in a first cohort of 2 patients, a second cohort of 4 patients is added under the "2 + 4" design. The "3 Plus 3" studies follow the same stopping rule. A third cohort of three patients is added to the "3 + 3 + 3" study if two out of every six participants in the first two cohorts experience a dose-limiting toxicity. The study is stopped if at least three out of nine individuals encounter a dose-limiting hazard. If one or two dose-limiting toxicities are noticed in the first three patients, the "best of 5" design mandates the addition of one more patient. If 2 dose-limiting toxicities are observed among the 4 treated individuals, another patient is recruited. If no dose-limiting toxicities are observed in 3, 1, or 2 of 5 patients, escalation is continued. The trial is terminated if three or more dose-limiting toxicities are observed.

Variations of the 3 + 3 design and the model-based design are combined in accelerated titration designs. The assignment of patients to doses is based on predetermined guidelines. Another application of the 3 + 3 design method is pharmacologically guided dose escalation. This is presuming that research using animal models accurately depict toxicities that are dose-limiting based on plasma drug concentrations. In the firststage, plasma exposure is extrapolated from preclinical data. To decide the next dose, pharmacokinetic information is then gathered for each patient.[56] The isotonic regression model fits an isotonic regression to accumulated data under the assumption that toxicity is nondecreasing with dose. The dose used is one whose predicted toxicity is believed to be most closely related to the maximum acceptable toxicity.[57] According on the number of patients who have been enrolled and are evaluable, the number who have dose-limiting toxicity (DLT), and the number who are still at risk of developing DLT, the "rolling six design" allows for the concurrent addition of 2 to 6 patients onto a dose level.[58] This strategy is helpful for paediatric populations and aims to reduce the length of the study when the dose range is known beforehand. The "biased coin up-and-down design" distributes a dose to each patient based on the toxicity data of the most recently finished subject, enables numerous patients to be treated concurrently, and demands that the treatment response or the toxicity evaluation be noticed rapidly.[59-61]

Model-based designs employ statistical models that compute a more accurate dose-toxicity curve using toxicity data from all enrolled patients in order to find a dose level that produces a probability of dose-limiting toxicity. The usage of Bayesian models is widespread. These models call for an estimation of (which describes the contour of the dose-toxicity curve). The Bayes theorem is used to adapt when toxicity is seen. The recommended doses for Phase II clinical trials are provided by these designs with a confidence interval. The first Bayesian model-based approach utilised in Phase I clinical trial designs was the ongoing reassessment method.[62] Experts who are familiar with the preclinical data or who have knowledge of comparable medications are consulted for the initial estimate of. Patients are administered the dose deemed to be most closely associated with the MTD, and an evaluation of the likelihood of a dose-limiting toxicity is computed for each new patient enrolled in the research. Once a predetermined condition is fulfilled, the trial is terminated. This approach has been modified to treat patients at the lowest starting dose level, increase doses only by one predetermined level at a time, and prevent dose escalation for the next patient if a previous patient experienced a dose-related adverse event. -reducing toxicity, managing several patients at the same dose level, and growing the patient cohort.[63-66] A different Bayesian strategy to get around the problem of patients receiving large toxic dosages was suggested: escalation with overdose control.[67] The time-to-event endpoint and the efficacy and toxicity techniques are two further model-based designs. These model-based techniques produce accurate target probabilities of DLT at the suggested dose for Phase II clinical trials without subjecting an excessive number of patients to an ineffective dose.

The use of alternate escalation of the agents in a series of dose levels, simultaneous escalation of both agents, escalation of one agent to the recommended dose for Phase II trials while maintaining the other agent at a fixed dose, and escalation of one agent to the recommended dose for Phase II trials while maintaining the other agent at a low dose have all been used as dose-escalation strategies in trials of agent combinations. Riviere and colleagues conducted a review and found that a classic or modified 3 + 3 dose

escalation strategy was employed in 88% of the trials. 6% was the determined median DLT rate. The starting dosages, dose levels, and dose escalation phases should maintain patient safety, treat as few patients as feasible at subtherapeutic doses, and identify the best pharmacological combinations for further study, according to the authors.[68] For molecularly targeted medicines with a confirmed meaningful target and a validated method for detecting target inhibition, no specific clinical trial designs have been developed.

2.1.8.3 Phase II Clinical Trials

The most successful dose (MSD), which is the dose that optimises the product of the chance of seeing no toxicity along with the probability of seeing a therapeutic response, is determined through phase I/II dose discovery studies. Phase II clinical trials analyse prospective efficacy and convincingly identify therapy benefit for the condition, whereas Phase I clinical research concentrate on determining the MTD. There is no expectation that the intervention will have any kind of therapeutic value. These studies, which involve bigger cohorts (between 100 and 300 patients), are carried out to evaluate the effectiveness of the medication and to carry out ongoing safety evaluations. The clinical researcher administers therapeutic doses that were identified during Phase I while keeping an eye on the patients. Trials are frequently held in a setting with multiple institutions. Phase II may be further broken down into Phase IIA, which are pilot clinical trials to assess efficacy and safety in selected populations with the disease or condition to be treated, diagnosed, or prevented (objectives may include dose-response, type of patient, frequency of dosing, or other identifiers of safety and efficacy), and Phase IIB, which are the most stringent trials intended to demonstrate efficacy. When the drug's intended use or hazardous consequences are revealed during this Phase II, the development process typically fails.

The effectiveness and quality of the Phase I research will determine the Phase II design. The kind of patient who is enrolled is a vulnerable element in both rounds. More exclusion criteria apply to patients in Phase II trials compared to those in Phase III trials. Designs for randomised clinical trials and case series have both been employed. Phase II clinical trial designs that are single stage or multistage are frequently created with the idea that only one endpoint is important. Based on Gehan's work, a variant of a two-stage design is a regularly used Phase II design.[69] Other designs feature a sequential element or several stages. Efficiency has been increased by using hybrid designs. Gehan provided an update on the statistical considerations of plans for Phase II cancer clinical trials, including a minimum patient plan, a two-stage decision theory approach, a limited patient accrual plan, a predictive probability plan, and a one-sample multiple testing method plan. The author offers suggestions for the strategy that will best serve the needs of the study.[70] Due to their adaptability and effectiveness, adaptive clinical trial designs based on gathered data at interim have also been applied in Phase II clinical studies. The researcher may be able to alter or redesign the experiment while the study is still in progress thanks to this design. However, because of ambiguous definitions, disagreements over sample size re-estimation techniques, and logistical challenges in implementing adaptable designs inside pre-existing trial frameworks, researchers have been hesitant to utilise them.[71] The FDA is aware with the research designs due to its examination of submissions using "well understood" designs that have been in use for years with associated statistical methodologies that are well established. The relative strengths and limitations of the "less well understood" study designs have not been fully assessed, no valid statistical methods have been created, and the FDA has little experience with submissions utilising the study designs. According to Chow et al., an adaptive design is one that permits modifications to trial protocols and/or statistical methods after the trial has begun without compromising the trial's validity and integrity.[72] There are several different adaptive clinical trial designs, such as adaptive randomization, adaptive group sequential, flexible sample size re-estimation, drop-the-losers, adaptive dose-finding, adaptive treatment switching, adaptive hypothesis, Phase I/II or II/III adaptive seamless trial design, and multiple adaptive.

2.1.8.4 Phase III Clinical Trials

The goal of phase III trials is to evaluate the effectiveness of the novel treatment to the current treatment on a large scale. These are the most thorough and rigorous kinds of clinical research studies looking at new treatments. The "pre-marketing phase" of clinical studies is right now. These studies are typically the most expensive and time-consuming. The trials could be challenging to plan and carry out. Trial designs have included randomised controlled trials (parallel design), uncontrolled trials (single therapy), historical controls, no randomised concurrent trials, factorial designs, and group sequential designs. Large groups (100 to 3000 people) are recruited. The clinical researcher and the patient's private doctor keep an eye on the patient. Clinical trials in the third phase can be further broken down into Phase IIIA trials, which are carried out after the effectiveness of the therapy has been established but before regulatory submission of a New Drug Application (NDA) or other dossier, and Phase IIIB trials, which are carried out following regulatory submission of an NDA or other dossier but before approval and launch.

The FDA issued guideline documents in the 1980s that said that efficacy should be proven through life extension, an increase in health-related quality of life, or a recognised substitute for one of these. The new therapy is typically approved for clinical usage if it produces a statistically significant improvement.[73] Overall survival, time to tumour progression, overall response rate, time to treatment failure, and patient-reported outcomes have been the traditional goals for trials. Overall survival has served as the benchmark for proving clinical benefits. When a medicine outperforms the standard of care for a serious and life-threatening condition, Subpart H permits rapid approval. Based on a surrogate endpoint that most likely forecasts clinical benefit, this statement. While randomised Phase III clinical trials have been the gold standard for supporting the approval of new drugs, issues with drug development have included limited clinical benefit in large RCTs, the ability to predict the outcome of a Phase III trial based on the results of a Phase II trial, toxicity assessment, the design of studies involving drug combinations, and trial costs.[74]

2.1.8.5 Phase IV Clinical Trials

Therapies that have been found to be safe, effective, and of high quality may be made available to the general public after receiving FDA approval. Both patients and their doctors anticipate benefits. Not all safety or efficacy concerns, nevertheless, have been resolved. The FDA mandates ongoing assessment following release to assess safety signals that could impact the benefit-risk ratio.[75-76] "All studies (other than regular surveillance) completed after medication approval and related to the approved indication" are included in these Phase IV trials. These are post-marketing follow-up investigations. The trials are centred on how medications function in everyday life. Anyone seeking medical attention from their doctor is eligible to receive the therapy. The effectiveness of treatment is tracked by their private doctor. Healthcare expenditures and outcomes are calculated, pharmacogenetics is researched, and the effectiveness and detection of uncommon or long-term adverse effects are assessed over a much bigger patient group and longer time period. A lot of patients and doctors may be involved, and new clinical indications for a medicine may be established.[77] An FDA condition for drug approval could be that a developer complete a Phase IV trial. Less than half of studies

are finished by developers, if they are even started at all.[78] A medicine may be taken off the market or limited to certain indications as a consequence of phase IV trials.

These trials were initially carried out for marketing purposes and were structured much like Phase III research. The inclusion and exclusion criteria for the investigations were identical to those of Phase III studies, and they were conducted at institutions with investigators experienced in clinical trials. Results did not correspond to what would occur normally. Innovative studies were created as a result to include regular physicians in uninformed research communities. The objectives have been widened to include things like evaluating the incidence of adverse responses, figuring out the consequences of long-term therapy administration, coming up with a novel clinical use for the therapy, assessing the therapy in higher risk populations, etc. The combination of clinical practise with medical research is a major cause for concern.[79]

Additionally known as post-marketing surveillance trials, this phase. They take place after a medication or gadget has received regulatory authority's approval for sale to consumers. At this point, pharmaceutical companies have several goals: (1) to compare a drug with other drugs already on the market; (2) to track a drug's long-term efficacy and impact on a patient's quality of life; and (3) to assess the cost-effectiveness of a drug therapy in comparison to other existing and new therapies. A medication or device may be pulled off the market as a consequence of a phase IV study, or usage limits may be imposed on the product depending on the study's findings.[80-82]

2.1.8.6 Phase V Clinical Trials

The effectiveness of a community-based research study is referred to by a new phrase used in the literature that is also known as "translational research." It is utilised to investigate a new clinical treatment into many different public health procedures. Phase V trials are typically referred to as "field research" since they are specifically created to assess whether the mechanism can be applied to a large sample size.[83-85]

The goal of this translational study is to "transition from bench to bedside." Comparative effectiveness research and community-based research are both included in phase V clinical studies. On acquired data, research is conducted. Every reported use is assessed. There is no patient monitoring. Its major objective is to ascertain whether a new therapy will be incorporated into widespread clinical practise. Cooperative extension programmes, evaluation, evidence-based programmes, research techniques, and research translation are filed under: cornell cooperative extension, policy, the learning centre, and evidence-based living.

REFERENCES

1. H Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011 Mar;162(6):1239-49. doi: 10.1111/j.1476-5381.2010.01127.x. PMID: 21091654; PMCID: PMC3058157.
2. Lipsky MS, Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract. 2001 Sep-Oct;14(5):362-7. PMID: 11572541.
3. Shultana, S. ., Maraz, K. M. ., Ahmed, A. ., Sultana, T. . and Khan, R. A. . (2021) "Drug design, discovery and development and their safety or efficacy on human body", *GSC Biological and Pharmaceutical Sciences*, 17(2), pp. 113–122. doi: 10.30574/gscbps.2021.17.2.0330.
4. Zhou SF, Zhong WZ. Drug Design and Discovery: Principles and Applications. Molecules. 2017 Feb 13;22(2):279. doi: 10.3390/molecules22020279. PMID: 28208821; PMCID: PMC6155886.
5. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003 Mar;22(2):151-85. doi: 10.1016/S0167-6296(02)00126-1. PMID: 12606142.
6. Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery. EMBO Rep. 2004 Sep;5(9):837-42. doi: 10.1038/sj.embor.7400236. PMID: 15470377; PMCID: PMC1299137.
7. Shultana, S. ., K. M. . Maraz, A. . Ahmed, T. . Sultana, and R. A. . Khan. "Drug Design, Discovery and Development and Their Safety or Efficacy on Human Body". *GSC Biological and Pharmaceutical Sciences*, vol. 17, no. 2, Nov. 2021, pp. 113-22, doi:10.30574/gscbps.2021.17.2.0330.
8. Shultana, S. ., K. M. . Maraz, A. . Ahmed, T. . Sultana, and R. A. . Khan. "Drug Design, Discovery and Development and Their Safety or Efficacy on Human Body". *GSC Biological and Pharmaceutical Sciences*, vol. 17, no. 2, Nov. 2021, pp. 113-22, doi:10.30574/gscbps.2021.17.2.0330.
9. Amol B. Deore, Jayprabha R. Dhumane, Hrushikesh V Wagh, Rushikesh B. Sonawane, The Stages of Drug Discovery and Development Process. Asian Journal of Pharmaceutical Research and Development. 2019; 7: 62-67.
10. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011 Mar;162(6):1239-49. doi: 10.1111/j.1476-5381.2010.01127.x. PMID: 21091654; PMCID: PMC3058157.
11. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today. 2012 Feb;17 Suppl:S24-30. doi: 10.1016/j.drudis.2011.12.008. Epub 2011 Dec 11. PMID: 22155646.
12. Croston GE. The utility of target-based discovery. Expert Opin Drug Discov. 2017 May;12(5):427-429. doi: 10.1080/17460441.2017.1308351. Epub 2017 Mar 23. PMID: 28306350.
13. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011 Mar;162(6):1239-49. doi: 10.1111/j.1476-5381.2010.01127.x. PMID: 21091654; PMCID: PMC3058157.
14. Aldewachi H, Al-Zidan RN, Conner MT, Salman MM. High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases. Bioengineering (Basel). 2021 Feb 23;8(2):30. doi: 10.3390/bioengineering8020030. PMID: 33672148; PMCID: PMC7926814.
15. https://www.slideshare.net/rahul_pharma/drug-discovery-and-development-10698574.
16. Daou A. COVID-19 Vaccination: From Interesting Agent to the Patient. Vaccines (Basel). 2021 Feb 3;9(2):120. doi: 10.3390/vaccines9020120. PMID: 33546347; PMCID: PMC7913564.

17. https://www.pharmatutor.org/articles/review-lead-optimization-techniques
18. Vetrivel, Dr.Umashankar & Subramanian, Gurunathan. (2015). DRUG DISCOVERY: AN APPRAISAL. International Journal of Pharmacy and Pharmaceutical Sciences. 7. 59-66.
19. https://www.nature.com/articles/nrd1523
20. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol. 2006 Apr;61(4):427-39. doi: 10.1111/j.1365-2125.2006.02588.x. PMID: 16542204; PMCID: PMC1885031.
21. Good Laboratory Practice For Nonclinical Studies, U.S. Code of Federal Regulations, Title 21, Chapter I, Part 58 April 1, 2000.
22. Gargiulo, G., 2018. Next-Generation in vivo Modeling of Human Cancers. Frontiers in Oncology, 8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192385/
23. Højelse, F., 2000. Preclinical Safety Assessment: In vitro - in vivo Testing. Pharmacology & Toxicology, 86, pp.6-7. https://pubmed.ncbi.nlm.nih.gov/10905745/
24. Lorian, V., 1988. Differences between in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy, 32(10), pp.1600-1601. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC175930/
25. Barile FA. Pri. nciples of Toxicological Testing. CRC Press, USA, 2008.
26. Friedman LM, Furberg CD, Demets DL. Fundamentals of clinical trials. 4th ed. New York: Springer Science and Business Media LLC; 2010.
27. Faqi AS. A comprehensive guide to toxicology in preclinical drug development. Waltham, MA: Elsevier; 2013.
28. Vogel HG. Drug Discovery and Evaluation 2nd edition. Springer, USA, 2002.
29. Karara AH, Edeki T, McLeod J, et al. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications. Journal of ClinicalPharmacology, 2010; 50:380– 391.
30. Browne, L.H. and Graham, P.H. (2014) Good Intentions and ICU-GCP: Trial Conduct Training Needs to Go beyond the ICH-GCP Document and include the Intention-to-Treat Principle. Clinical Trials, 11, 629-634. http://dx.doi.org/10.1177/1740774514542620
31. Ohmann, C., Kuchinke, W., Canham, S., Lauritsen, J., Salas, N., Schade-Brittinger, C., et al. (2011) Standard Requirements for GCP-Compliant Data Management in Multinational Clinical Trials. Trials, 12, 85. http://dx.doi.org/10.1186/1745-6215-12-85
32. Rock, E.P., Molloy, V.J. and Humphrey, J.S. (2010) GCP Data Quality for Early Clinical Development. Clinical Cancer Research, 16, 1756-1763. http://dx.doi.org/10.1158/1078-0432.CCR-09-3267
33. Switula, D. (2000) Principles of Good Clinical Practice (GCP) in Clinical Research. Science and Engineering Ethics, 6, 71-77. http://dx.doi.org/10.1007/s11948-000-0025-z
34. Vijayananthan, A. and Nawawi, O. (2008) The Importance of Good Clinical Practice Guidelines and Its Role in Clinical Trials. Biomedical Imaging and Intervention Journal, 4, e5. http://dx.doi.org/10.2349/biij.4.1.e5
35. Chalmers, T.C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., et al. (1981) A Method for Assessing the Quality of a Randomized Control Trial. Controlled Clinical Trials, 2, 31-49. http://dx.doi.org/10.1016/0197-2456(81)90056-8
36.
37. Haahr, M.T. and Hróbjartsson, A. (2006) Who Is Blinded in Randomized Clinical Trials? A Study of 200 Trials and a Survey of Authors. Clinical Trials, 3, 360-365
38. Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, J.M., Gavaghan, D.J., et al. (1996) Assessing the Quality of Reports of Randomizing Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12. http://dx.doi.org/10.1016/0197-2456(95)00134-4
39.
40. Moher, D., Jadad, A.R., Nichol, G., Penman, M., Tugwell, P. and Walsh, S. (1995) Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists. Controlled Clinical Trials, 16, 62-73. http://dx.doi.org/10.1016/0197-2456(94)00031-W
41. Torgerson, D.J. and Roland, M. (1998) What Is Zelen's Design. British Medical Journal, 316, 606-608. http://dx.doi.org/10.1136/bmj.316.7131.606
42. E-Source Behavioral & Social Sciences Research. Clinical Trials. www.esourceresearch.org
43. Stanley, K. (2007) Design of Randomized Controlled Trials. Circulation, 115, 1164-1169. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.594945
44. DeMets, D., Friedman, L. and Furberg, C. (2010) Fundamentals of Clinical Trials. 4th Edition, Springer, Berlin.
45. Rogers, M.A. (2009) What Are the Phases of Intervention Research? American Speech-Language-Hearing Association, Rockville.
46. Becich, M.J. (2007) Lessons Learned from the Shared Pathology Informatics Network (SPIN): A Scalable Network for Tanslational Research and Public Health. Journal of the American Medical Informatics Association, 14, 534-535. http://dx.doi.org/10.1197/jamia.M2477
47. US Department of Health and Human Services Food and Drug Administration (2012) Innovation or Stagnation: Challenges and Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
48. Lloyd, I. (2002-2003) New Technologies, Products in Development, and Attrition Rates: R&D Revolution Still around the Corner. PARAXEL's Pharmaceutical R&D Statistical Sourcebook. PAREXEL International Corporation, Wal-tham
49. Boston Consulting Group (2002-2003) A Revolution in R&D: How Genomics and Genetics Will Affect Drug Development Costs and Times. PARAXEL's Pharmaceutical R&D Statistical Sourcebook. PAREXEL International Corporation, Waltham

50. Kinders, R., Parchment, R.E., Ji, J., Kummar, S., Murgo, A.J., Gutierrez, M., et al. (2007) Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. Molecular Interventions, 7, 325-334. http://dx.doi.org/10.1124/mi.7.6.9
51. Kummar, S., Kinders, R., Rubinstein, L., Parchment, R.E., Murgo, A.J., Collins, J., et al. (2007) Compressing Drug Development Timelines in Oncology Using Phase "0" Trials. Nature Reviews Cancer, 7, 131-139. http://dx.doi.org/10.1038/nrc2066
52. Marchetti, S. and Schellens, J.H.M. (2007) The Impact of FDA and EMEA Guidelines on Drug Development in Relation to Phase 0 Trials. British Journal of Cancer, 97, 577-581. http://dx.doi.org/10.1038/sj.bjc.6603925
53. Schellens, J.H.M. (2009) Phase 0 (Zero) Clinical Trials: More than Zero Benefits? European Journal of Cancer, 45, 728-729. http://dx.doi.org/10.1016/j.ejca.2009.01.022
54. Le Tourneau, C., Lee, J.J. and Siu, L.L. (2009) Dose Escalation Methods in Phase I Cancer Clinical Trials. Journal of the National Cancer Institute, 101, 708-720. http://dx.doi.org/10.1093/jnci/djp079
55. Storer, B.E. (1989) Design and Analysis of Phase I Clinical Trials. Biometrics, 45, 795-798. http://dx.doi.org/10.2307/2531693
56. Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F.R. and Porter, A. (2007) Translation of Innovative Designs into Phase I Trials. Journal of Clinical Oncology, 25, 4982-4986. http://dx.doi.org/10.1200/JCO.2007.12.1012
57. Storer, B.E. (2001) An Evaluation of Phase I Clinical Trial Designs in the Continuous Dose-Response Setting. Statistics in Medicine, 20, 2399-2408. http://dx.doi.org/10.1002/sim.903
58. Graham, M.A. and Workman, P. (1992) The Impact of Pharmacokinetically Guided Dose Escalation Strategies in Phase I Clinical Trials: Critical Evaluation and Recommendations for Future Studies. Annals of Oncology, 3, 339-347.
59. Leung DH, Wang Y. Isotonic designs for phase I trials. Control Clin Trials. 2001 Apr;22(2):126-38. doi: 10.1016/s0197-2456(00)00132-x. PMID: 11306151.
60. Skolnick, J.M., Barrett, J.S., Jayaraman, B., Patel, D. and Adamson, P.C. (2008) Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design. Journal of Clinical Oncology, 26, 190-195. http://dx.doi.org/10.1200/JCO.2007.12.7712
61. Durham, S.D., Flournoy, N. and Rosenberger, W.F. (1997) A Random Walk Rule for Phase I Clinical Trials. Biometrics, 53, 745-760. http://dx.doi.org/10.2307/2533975
62. Ivanova, A., Montazer-Haghighi, A., Mohanty, S.G. and Durham, S.D. (2003) Improved Up-and-Down Designs for Phase I Trials. Statistics in Medicine, 22, 69-82. http://dx.doi.org/10.1002/sim.1336
63. Stylianou, M. and Follmann, D.A. (2004) The Accelerated Biased Coin Up-and-Down Design in Phase I Trials. Journal of Biopharmaceutical Statistics, 14, 249-260. http://dx.doi.org/10.1081/BIP-120028518
64. O'Quigley, J., Pepe, M. and Fisher, L. (1990) Continual Reassessment Method: A Practical Design for Phase I Clinical Trials in Cancer. Biometrics, 46, 33-48. http://dx.doi.org/10.2307/2531628
65. Faries, D. (1994) Practical Modifications of the Continual Reassessment Method for Phase I Cancer Clinical Trials. Journal of Biopharmaceutical Statistics, 4, 147-164. http://dx.doi.org/10.1080/10543409408835079
66. Goodman, S.N., Zahurk, M.L. and Piantadosi, S. (1995) Some Practical Improvements in the Continual Reassessment Method for Phase I Studies. Statistics in Medicine, 14, 1149-1161. http://dx.doi.org/10.1002/sim.4780141102
67. Moller, S. (1995) An Extension of the Continual Reassessment Methods Using a Preliminary Up-and-Down Design in a Dose Finding Study in Cancer Patients in Order to Investigate a Greater Range of Doses. Statistics in Medicine, 14, 911-922. http://dx.doi.org/10.1002/sim.4780140909
68. Piantadosi, S., Fisher, J.D. and Grossman, S. (1998) Practical Implementation of a Modified Continual Reassessment Method for Dose-Finding Trials. Cancer Chemotherapy and Pharmacology, 41, 429-436. http://dx.doi.org/10.1007/s002800050763
69. Rogatko, A., Babb, J.S., Tighiouart, M., Khuri, F.R. and Hudes, G. (2005) New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I. Clinical Cancer Research, 11, 5342-5346. http://dx.doi.org/10.1158/1078-0432.CCR-05-0458
70. Riviere, M.K., Le Tourneau, C., Paoletti, X., Dubois, F. and Zohar, S. (2014) Designs of Drug-Combination Phase I Trials in Oncology: A Systematic Review of the Literature. Annals of Oncology. http://dx.doi.org/10.1093/annonc/mdu516
71. Gehan, E.A. (1961) The Determination of the Number of Patients Required in a Preliminary and a Follow-Up Trial of a New Chemotherapeutic Agent. Journal of Chronic Diseases, 13, 346-353. http://dx.doi.org/10.1016/0021-9681(61)90060-1
72. Gehan, E.A. (1986) Update on Planning of Phase II Clinical Trials. Drugs under Experimental and Clinical Research, 12, 43-50.
73. Coffey, C.S. and Kairalla, J.A. (2008) Adaptive Clinical Trials: Progress and Challenges. Drugs in R&D, 9, 229-242. http://dx.doi.org/10.2165/00126839-200809040-00003
74. Chow, S.C., Chang, M. and Pong, A. (2005) Statistical Consideration of Adaptive Methods in Clinical Development. Journal of Biopharmaceutical Statistics, 15, 575-591. http://dx.doi.org/10.1081/BIP-200062277
75. Pazdur, R. (2008) Endpoints for Assessing Drug Activity in Clinical Trials. The Oncologist, 13, 19-21. http://dx.doi.org/10.1634/theoncologist.13-S2-19
76. Ocana, A., Amir, E., Vera-Badillo, F., Seruga, B. and Tannock, I.F. (2013) Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. Cancer Research, 19, 4931-4940.
77. Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs (2012) Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Institute of Medicine of the National Academics, Washington DC.
78. Mello, M.M., Goodman, S.N. and Faden, R.R. (2012) Ethical Considerations in Studying Drug Safety—The Institute of Medicine Report. The New England Journal of Medicine, 367, 959-964. http://dx.doi.org/10.1056/NEJMhle1207160
79. Bernabe, R.D.L.C., van Thiel, G.J.M.W., Raaijmakers, J.A.M. and van Delden, J.J.M. (2014) The Fiduciary Obligation of the Physician-Researcher in Phase IV Trials. BMC Medical Ethics, 15, 11. http://dx.doi.org/10.1186/1472-6939-15-11
80. Fontanarosa, P.B., Rennie, D. and DeAngelis, C.D. (2004) Postmarketing Surveillance—Lack of Vigilance, Lack of Trust. Journal of the American Medical Association, 292, 2647-2650. http://dx.doi.org/10.1001/jama.292.21.2647

81. van Thiel, G.J.M.W. and van Delden, J.J.M. (2008) Phase IV Research: Innovation in Need of Ethics. Journal of Medical Ethics, 34, 415-416. http://dx.doi.org/10.1136/jme.2007.023911
82. . The Lancet (2009). "Phase 0 trials: A platform for drug development?". The Lancet. 374 (9685): 176–118
83. Yang, Z. J., et al. (2010). "Motivation for Health Information Seeking and Processing About Clinical Trial Enrollment." Health Communication 25(5): 423-436.
84. Life Sciences Strategy Group, (May 2009) "Clinical Trial Technology Utilization, Purchasing Preferences & Growth Outlook" Syndicated Publication,
85. Christopher P. Adams and Van V. Brantner. Estimating the cost of new drug development: Is It Really $802 million?, Health affairs. 2006; 25: 420-428